Frailty may be key to predicting surgery survival in the very old

NCT ID NCT07440095

Completed Knowledge-focused Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examines whether frailty and simple blood tests can predict which patients aged 80 and older are most likely to die within 30 days after major abdominal surgery. Researchers will review records of 100 patients to see if a frailty index and lab markers like albumin and hemoglobin offer better risk prediction than standard methods. The goal is to improve surgical decision-making and pre-surgery care for the oldest patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better identify which very elderly patients are at highest risk after major abdominal surgery, leading to more informed decisions and possibly pre-surgery strengthening programs.
What could go wrong: This is a small, retrospective study (100 patients) from a single hospital, so results may not apply to all older adults. It only looks at risk factors, not a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABDOMEN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABDOMEN CANCER AGED, 80 AND OVER FRAILTY POSTOPERATIVE COMPLICATIONS

Contacts and locations

Locations

Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Rea

Ankara, Yenimahalle, 06200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.